<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140530</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02103</org_study_id>
    <secondary_id>AZ 504/02</secondary_id>
    <nct_id>NCT00140530</nct_id>
  </id_info>
  <brief_title>Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)</brief_title>
  <official_title>A Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Prevention of Restenosis (ISAR-TEST-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayerische Forschungsstiftung Muenchen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of nonpolymer-based rapamycin-eluting
      stent compared to standard polymer-based paclitaxel-eluting stent to reduce reblockage of
      coronary arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug-eluting stents represent a major advance in the treatment of restenosis. They have
      dramatically reduced the need of repeat revascularization procedures, and, thanks to the
      excellent results obtained in various patient subsets, these devices are now used in almost
      90% of the stent implantation procedures performed in US hospitals. Along with the increasing
      number of patients receiving drug-eluting stents and availability of long-term follow-up
      data, concern has arisen regarding the safety of these devices. At the core of this concern
      is the potential for increased inflammatory and thrombogenic responses and their
      life-threatening consequences associated with the polymers employed for the delivery of
      antirestenotic agents. A growing interest has been shown on polymer-free stents with a
      microporous surface as an alternative to stents employing polymeric coating for local drug
      delivery. Recently, we developed a mobile system which enables coating in the catheterization
      laboratory of polymeric free stents with different drug doses or combinations. Using a
      porcine coronary model of restenosis, we found that coating with rapamycin of a polymer-free
      microporous stent is feasible and effectively reduces neointimal proliferation. More
      recently, in a clinical study in which the efficacy of several doses of rapamycin was
      assessed, we showed that non-polymer coating with rapamycin is safe and leads to a
      dose-dependent reduction in restenosis. While the advantage deriving from the lack of
      polymeric cover in on-site coated rapamycin-eluting stents is readily understandable, their
      relative efficacy as compared with commercially available polymer-based drug-eluting stents
      has yet to be evaluated.

      Comparison:

      Polymer-free microporous stents coated with rapamycin versus standard polymer-based,
      paclitaxel-eluting stents
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late luminal loss</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic restenosis at follow-up angiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for target lesion revascularization due restenosis at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Due to randomisation patients got a Paclitaxel-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Due to randomization patients got a Rapamycin-eluting stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting stent (Taxus)</intervention_name>
    <description>patients has been implanted the Paclitaxel-eluting stent.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Taxus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapamycin-eluting stent</intervention_name>
    <description>patients has been implanted the Rapamycin-eluting stent.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at least 18 years old

          -  Stable or unstable angina or a positive stress test

          -  &quot;de novo&quot; coronary artery lesions

          -  Written informed consent

        Exclusion Criteria:

          -  Myocardial infarction within 48 h. before enrollment

          -  Target lesion located in left main trunk

          -  Contraindication or known allergy to aspirin, heparin, thienopyridines, rapamycin,
             paclitaxel or stainless steel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schomig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schömig A; investigators of the individualizable durg-eluting Stent System to Abrogate Restenosis Project. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005 Aug;26(15):1475-81. Epub 2005 Jun 23.</citation>
    <PMID>15975990</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004 Jan 15;350(3):221-31.</citation>
    <PMID>14724301</PMID>
  </reference>
  <reference>
    <citation>Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002 Nov 19;106(21):2649-51.</citation>
    <PMID>12438288</PMID>
  </reference>
  <reference>
    <citation>Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004 Feb 17;109(6):701-5. Epub 2004 Jan 26.</citation>
    <PMID>14744976</PMID>
  </reference>
  <results_reference>
    <citation>Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schömig A; Intracoronary Stenting and Angiographic Restenosis--Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006 Jan 17;113(2):273-9. Epub 2006 Jan 3.</citation>
    <PMID>16391155</PMID>
  </results_reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

